文献

J-GLOBAL ID：201702265173370320   整理番号：17A1960423

限局性前立腺癌に対する抗アンドロゲン2 ヒドロキシフルトアミドの前立腺内修飾放出製剤【Powered by NICT】

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer

著者 (120件)： Tammela Teuvo L. (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Tammela Teuvo L. (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Tammela Teuvo L. (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Tammela Teuvo L. (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Tammela Teuvo L. (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Tammela Teuvo L. (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Tammela Teuvo L. (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Tammela Teuvo L. (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Tammela Teuvo L. (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Haeggman Michael (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Haeggman Michael (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Haeggman Michael (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Haeggman Michael (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Haeggman Michael (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Haeggman Michael (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Haeggman Michael (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Haeggman Michael (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Haeggman Michael (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Ladjevardi Sam (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Ladjevardi Sam (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Ladjevardi Sam (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Ladjevardi Sam (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Ladjevardi Sam (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Ladjevardi Sam (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Ladjevardi Sam (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Ladjevardi Sam (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Ladjevardi Sam (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Taari Kimmo (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Taari Kimmo (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Taari Kimmo (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Taari Kimmo (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Taari Kimmo (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Taari Kimmo (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Taari Kimmo (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Taari Kimmo (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Taari Kimmo (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Isotalo Taina (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Isotalo Taina (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Isotalo Taina (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Isotalo Taina (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Isotalo Taina (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Isotalo Taina (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Isotalo Taina (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Isotalo Taina (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Isotalo Taina (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Lennernaes Hans (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Lennernaes Hans (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Lennernaes Hans (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Lennernaes Hans (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Lennernaes Hans (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Lennernaes Hans (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Lennernaes Hans (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Lennernaes Hans (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Lennernaes Hans (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Weis Jan (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Weis Jan (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Weis Jan (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Weis Jan (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Weis Jan (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Weis Jan (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Weis Jan (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Weis Jan (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Weis Jan (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  von Below Catrin (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  von Below Catrin (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  von Below Catrin (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  von Below Catrin (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  von Below Catrin (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  von Below Catrin (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  von Below Catrin (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  von Below Catrin (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  von Below Catrin (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Wassberg Cecilia (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Wassberg Cecilia (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Wassberg Cecilia (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Wassberg Cecilia (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Wassberg Cecilia (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Wassberg Cecilia (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Wassberg Cecilia (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Wassberg Cecilia (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Wassberg Cecilia (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Lennernaes Bo (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Lennernaes Bo (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Lennernaes Bo (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Lennernaes Bo (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Lennernaes Bo (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Lennernaes Bo (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Lennernaes Bo (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Lennernaes Bo (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Lennernaes Bo (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Tolf Anna (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Tolf Anna (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Tolf Anna (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Tolf Anna (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Tolf Anna (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Tolf Anna (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Tolf Anna (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Tolf Anna (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Tolf Anna (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Axen Niklas (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Axen Niklas (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Axen Niklas (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Axen Niklas (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Axen Niklas (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Axen Niklas (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Axen Niklas (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Axen Niklas (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Axen Niklas (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Golander Carl-Gustaf (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Golander Carl-Gustaf (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Golander Carl-Gustaf (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland) ,  Golander Carl-Gustaf (Department of Urology, Uppsala University Hospital (MH, SL), Uppsala, Sweden) ,  Golander Carl-Gustaf (Radiology, Department of Surgical Sciences (JW, CvB, CW), Uppsala University, Uppsala, Sweden) ,  Golander Carl-Gustaf (Department of Pharmacy (HL), Uppsala University, Uppsala, Sweden) ,  Golander Carl-Gustaf (Department of Immunology Genetics and Pathology (AT), Uppsala University, Uppsala, Sweden) ,  Golander Carl-Gustaf (LIDDS AB (NA, CGG), Uppsala, Sweden) ,  Golander Carl-Gustaf (Department of Oncology, University of OErebro (BL), OErebro, Sweden) ,  Ahlstrom Hakan (Department of Urology, Tampere University Hospital and University of Tampere (TLT), Tampere, Finland) ,  Ahlstrom Hakan (Department of Urology, Helsinki University Hospital (KT), Helsinki, Finland) ,  Ahlstrom Hakan (Department of Urology, Paeijaet-Haeme Central Hospital (TI), Lahti, Finland)
資料名： Journal of Urology  (Journal of Urology)
巻： 198  号： 6  ページ： 1333-1339  発行年： 2017年 
JST資料番号： B0074B  ISSN： 0022-5347  CODEN： JOURA  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 限局性前立腺癌の男性における抗アンドロゲン2 ヒドロキシフルトアミド(NanoZolid)の新規前立腺内デポー製剤の忍容性,安全性および抗腫瘍効果を検討した。二臨床試験,LPC002とLPC003は全男性47人の中で行った。定式化は超音波ガイド下前立腺にtransrectally注入した。LPC002では前立腺特異抗原と前立腺体積に及ぼす影響は24名の患者で6か月間測定した。LPC003では抗腫瘍効果は23名の患者で6または8週間病理組織学と磁気共鳴イメージングを含む分光法により評価した。各研究では血しょう中のテストステロンおよび2 ヒドロキシフルトアミドはクオリティオブライフ要因と同様に測定された。LPC002(平均投与量690mg)では前立腺特異抗原と前立腺体積の減少が観察された。平均天底前立腺特異抗原と前立腺体積はベースラインより24.9%と14.0%であった。920と1,740mg/LPC003における線量を増加させると,平均前立腺特異抗原は6と8週間後に16%および23%を減少した。磁気共鳴イメージングと磁気共鳴分光法は,形態学的変化と治療後の代謝産物濃度の全体的減少を示し,抗腫瘍応答を示した。注射はホルモン関連副作用をもたらさなかった。三重篤な有害事象は報告されており,全ての経口抗生物質治療により回復した。2 ヒドロキシフルトアミドデポー製剤の前立腺内注射は抗腫瘍作用を示し,安全かつ許容可能であることが分かった。しかし,優れた抗癌効果のための高用量と良好な線量分布を示唆した。Copyright 2018 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： NMRイメージング ,  患者 ,  前立腺腫瘍 ,  前立腺特異抗原 ,  治療法 ,  *前立腺 ,  放射線量 ,  臨床試験 ,  男性 ,  安全性 ,  代謝産物 ,  抗腫瘍作用 ,  クオリティオブライフ ,  ステロイド ,  エノン ,  脂環式アルコール ,  脂環式ケトン
準シソーラス用語： 前立腺体積 , 【Automatic Indexing@JST】

著者キーワード (5件)： 前立腺腫瘍 ,  前立腺特異抗原 ,  アンドロゲンきっ抗薬 ,  遅効製剤 ,  硫酸カルシウム

分類 (1件)： 泌尿生殖器の腫よう  (GM04000S)

物質索引 (1件)： テストステロン

タイトルに関連する用語 (6件)： 限局性前立腺癌 ,  抗アンドロゲン ,  前立腺 ,  修飾 ,  放出 ,  製剤